Get access
Clinical & Experimental Allergy

Benefits of progestin contraception in non-allergic angioedema

Authors

  • C. Saule,

    1. Gynaecological Endocrinology Unit, Paris Descartes University, Port Royal Cochin, APHP, Paris, France
    Search for more papers by this author
  • I. Boccon-Gibod,

    1. Internal Medicine Department, University Hospital of Grenoble, Grenoble, France
    2. Centre National des Angioedèmes à kinines (CREAK), University Hospital of Grenoble, Grenoble, France
    Search for more papers by this author
  • O. Fain,

    1. Internal Medicine Department, Jean Verdier Hospital, APHP, Bondy, France
    2. Centre National des Angioedèmes à kinines (CREAK), University Hospital of Grenoble, Grenoble, France
    Search for more papers by this author
  • G. Kanny,

    1. Internal Medicine Department, University Hospital of Nancy, Nancy, France
    2. Centre National des Angioedèmes à kinines (CREAK), University Hospital of Grenoble, Grenoble, France
    Search for more papers by this author
  • G. Plu-Bureau,

    1. Gynaecological Endocrinology Unit, Paris Descartes University, Port Royal Cochin, APHP, Paris, France
    Search for more papers by this author
  • L. Martin,

    1. Dermatology Department, University Hospital of Angers, Angers, France
    2. Centre National des Angioedèmes à kinines (CREAK), University Hospital of Grenoble, Grenoble, France
    Search for more papers by this author
  • D. Launay,

    1. Internal Medicine Department, University Hospital of Lille, Lille, France
    2. Centre National des Angioedèmes à kinines (CREAK), University Hospital of Grenoble, Grenoble, France
    Search for more papers by this author
  • L. Bouillet,

    1. Internal Medicine Department, University Hospital of Grenoble, Grenoble, France
    2. Centre National des Angioedèmes à kinines (CREAK), University Hospital of Grenoble, Grenoble, France
    Search for more papers by this author
  • A. Gompel

    Corresponding author
    1. Centre National des Angioedèmes à kinines (CREAK), University Hospital of Grenoble, Grenoble, France
    • Gynaecological Endocrinology Unit, Paris Descartes University, Port Royal Cochin, APHP, Paris, France
    Search for more papers by this author

Correspondence:

A. Gompel, Gynaecological Endocrinology Unit, Paris Descartes University, Port Royal Cochin, APHP, 53 Av.de l'Observatoire, Paris, 75014. France. E-mail: anne.gompel@cch.aphp.fr

Summary

Background

Hereditary angioedema attacks can be induced or worsened by oral contraceptive containing oestrogens.

Objectives

The purpose of this study was to assess the impact of progestin contraceptives on angioedema attacks.

Methods

We conducted a French retrospective, multi-centre study of progestin contraception in women with non-allergic angioedema, including hereditary angioedema type I, II and III and idiopathic angioedema. Patients were classified into four groups according to frequency of attacks. We evaluated the effects of progestin on the mean number of attacks and compared the number of patients in each group before and under progestin contraception. The influence of hormonal factors on the course of angioedema was also assessed.

Results

Fifty-five women were included: mean age was 32.1 years (16–52) and mean follow-up 32.4 months (SD:29). Fourteen women were classified as type I (25.4%), two as type II (3.6%) and 19 as type III (34%) and 20 were idiopathic (36%). Seventeen patients were taking a low dose progestin-only pill (POP), 24 antigonadotropic progestins (AGP) and 14 both successively. Total or partial improvement was observed in 81.8% (45/55) of the patients and more frequently in those on an AGP agent (34 patients, 89.5%) than on POP (19 patients, 61.3%) (P = 0.013).

Conclusions & Clinical Relevance

This is the first study evaluating the interest of antigonadotropic progestin contraception in a series of women with non-allergic angioedema. Progestins, especially antigonadotropic progestins, appear to convey a marked benefit in most cases. Antigonadotropic progestins could thus be recommended as adjuvant treatment in childbearing women with non-allergic angioedema.

Get access to the full text of this article

Ancillary